-
H.C. Wainwright Starts Rein Therapeutics (RNTX) at Buy
-
Rein Therapeutics publishes data on IPF drug candidate in iScience journal
-
Brookline Capital Markets Downgrades Rein Therapeutics (RNTX) to Hold
-
Rein Therapeutics secures up to $21 million in flexible financing agreements
-
Rein Therapeutics (RNTX) Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
-
Rodman & Renshaw Starts Rein Therapeutics (RNTX) at Buy
-
Aileron Therapeutics (ALRN) Announces Rebranding to Rein Therapeutics (RNTX)

